Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Free Report) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 136,100 shares, a decrease of 36.9% from the June 15th total of 215,600 shares. Currently, 5.1% of the shares of the company are sold short. Based on an average daily volume of 403,300 shares, the days-to-cover ratio is presently 0.3 days.
Seelos Therapeutics Price Performance
NASDAQ SEEL traded down $0.09 during trading on Friday, hitting $0.58. 1,165,714 shares of the company’s stock traded hands, compared to its average volume of 1,193,846. Seelos Therapeutics has a 12-month low of $0.47 and a 12-month high of $398.40. The business has a 50 day moving average of $1.16 and a 200-day moving average of $4.92.
Seelos Therapeutics (NASDAQ:SEEL – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($1.60) earnings per share for the quarter. The firm had revenue of $0.58 million during the quarter.
Institutional Investors Weigh In On Seelos Therapeutics
About Seelos Therapeutics
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
Recommended Stories
- Five stocks we like better than Seelos Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Top 3 Defense Stocks That Should Be on Your Radar
- The Role Economic Reports Play in a Successful Investment Strategy
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.